Obalon Therapeutics Statistics Share Statistics Obalon Therapeutics has 1.79M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 1.79M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 442.47K Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 441.28K, so 0% of the outstanding
shares have been sold short.
Short Interest 441.28K Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.95 and the forward
PE ratio is null.
Obalon Therapeutics's PEG ratio is
0.01.
PE Ratio -0.95 Forward PE n/a PS Ratio 7.34 Forward PS n/a PB Ratio 2.5 P/FCF Ratio -1.1 PEG Ratio 0.01
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Obalon Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.55,
with a Debt / Equity ratio of 2.22.
Current Ratio 1.55 Quick Ratio 1.55 Debt / Equity 2.22 Debt / EBITDA -0.9 Debt / FCF -0.98 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $794K Profits Per Employee $-6.17M Employee Count 2 Asset Turnover 0.15 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is -1.24, so Obalon Therapeutics's
price volatility has been lower than the market average.
Beta -1.24 52-Week Price Change n/a 50-Day Moving Average n/a 200-Day Moving Average n/a Relative Strength Index (RSI) n/a Average Volume (20 Days) 1,508,029
Income Statement In the last 12 months, Obalon Therapeutics had revenue of 1.59M
and earned -12.33M
in profits. Earnings per share was -1.59.
Revenue 1.59M Gross Profit 584K Operating Income -10.64M Net Income -12.33M EBITDA -11.49M EBIT n/a Earnings Per Share (EPS) -1.59
Full Income Statement Balance Sheet The company has 3.9M in cash and 10.36M in
debt, giving a net cash position of -6.46M.
Cash & Cash Equivalents 3.9M Total Debt 10.36M Net Cash -6.46M Retained Earnings -184.76M Total Assets 120M Working Capital 5.11M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -10.41M
and capital expenditures -171K, giving a free cash flow of -10.58M.
Operating Cash Flow -10.41M Capital Expenditures -171K Free Cash Flow -10.58M FCF Per Share -1.36
Full Cash Flow Statement Margins Gross margin is 36.78%, with operating and profit margins of -670.15% and -776.7%.
Gross Margin 36.78% Operating Margin -670.15% Pretax Margin -776.7% Profit Margin -776.7% EBITDA Margin -723.61% EBIT Margin -670.15% FCF Margin -666.25%
Dividends & Yields OBLN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for OBLN.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 16, 2021. It was a
backward
split with a ratio of 1:3.
Last Split Date Jun 16, 2021 Split Type backward Split Ratio 1:3
Scores Altman Z-Score -0.09 Piotroski F-Score 3
